_________________________________________________________________________________________________________ Veranova

of protection required to manufacture both APIs and controlled substances .” As a Home Office licensed operation , the Edinburgh site is regularly audited to ensure its processes are sufficient and compliant with regulations .

The recent investments have enabled Veranova to improve its containment capabilities by adding engineering controls and enhanced layers of protection which enhance safety and eliminate the risk of cross-contamination . “ Our strategy to prevent cross-contamination is incorporated into site procedures , ensuring that our products are fit for intended use , comply with requirements of the marketing authorization and do not , ultimately , place patients at risk ,” David adds .

“ Similar to health and safety policies , cross-contamination is not a one-off exercise . Instead , we ’ re constantly taking further steps as part of our day-to-day equipment

management . These steps are intended to provide solutions that can be easily integrated into our daily operations .”

While the Edinburgh facility dominates our conversation with its general manager , it is just one site in Veranova ’ s strategic network of locations within the US and European pharmaceutical markets . Having recently experienced extensive investment , the Edinburgh site is poised to support the company ’ s growth , both in the UK and beyond .

David concludes : “ I look forward to seeing Veranova flourish and expand in the generic API and CDMO space , leveraging our extensive capabilities and technologies in the manufacturing of complex APIs , controlled substances , and highly potent compounds .” ■

www . veranova . com

| Containment Isolators | Sterility Test Isolators | Fume Cupboards

Find out more >

manufacturing-today . com 177